Subscribe free

Cytoreductive Surgery & Peritoneum ·

CRS/HIPEC improves survival in small bowel adenocarcinoma patients

A systematic review and meta-analysis of 746 patients revealed that cytoreduction and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) significantly enhances median overall survival to 32.3 months, compared to 14.5 months with systemic chemotherapy alone. In patients undergoing complete cytoreduction, the study reported a major morbidity rate of 20.7% and a mortality rate of 1.7% associated with CRS/HIPEC. These findings suggest that CRS/HIPEC may offer a viable treatment option for select patients with low-volume peritoneal carcinomatosis.

Journal Article by Fernando DG, Sparapani R and Mogal H in J Surg Oncol

© 2024 Wiley Periodicals LLC.

read the whole article in J Surg Oncol

open it in PubMed

Summaries are written to help you decide what to read. They do not replace the full paper.

Free · 5 minutes a day

Get every new paper in Cytoreductive Surgery & Peritoneum.

Plus the Daily Selection: the five most relevant papers of the day, each cut to its key points.

Specialty newsletters: every new paper in your field, as a list of titles linked to the source. Daily Selection: the five that matter, cut to their key points.

FreeNo spamOne-click unsubscribe

More in Cytoreductive Surgery & Peritoneum

The latest stitches

Ann Surg Oncol28 Aug 2026

Prophylactic HIPEC Improves Survival in Advanced Colorectal Cancer

Prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC) significantly enhances peritoneal metastasis-free survival and disease-free survival in patients with locally advanced colorectal cancer, though overall survival rates and complication rates remain unchanged.

All papers in Cytoreductive Surgery & Peritoneum →